Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + FOLFOX-HAIC
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Hepatic Arterial Infusion
01
Overview
This combination therapy consists of the PD-1 inhibitor sintilimab and the FOLFOX chemotherapy regimen (oxaliplatin, leucovorin, and fluorouracil) administered via hepatic arterial infusion chemotherapy (HAIC). It is being investigated by Sun Yat-sen University as a conversion therapy for patients with potentially resectable locally advanced hepatocellular carcinoma (HCC). The rationale is that HAIC provides high local concentrations of chemotherapy directly to the liver with reduced systemic toxicity, while PD-1 inhibition enhances the anti-tumor immune response. This synergistic approach aims to improve objective response rates and increase the conversion rate to surgical resection in patients who were initially ineligible for R0 resection.
- Brand names
- Tyvyt
- Other names
- HAIC+PD1Sintilimab plus HAICFOLFOX-HAIC plus SintilimabHAIC-Sun Yat-sen University-hepatocellular carcinoma
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on sintilimab + FOLFOX-HAIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + FOLFOX-HAIC.